J-S. Lee - Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 40 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)

B.J. Solomon,J.S. Ahn, R. Dziadziuszko, F. Barlesi, M. Nishio, D.H. Lee,J-S. Lee,W-Z. Zhong, H. Horinouchi, W. Mao, M.J. Hochmair,F. de Marinis,

Annals of Oncology (2023): S1295-S1296

引用0浏览0引用

1609P A machine learning-based prognostic model to predict survival in patients with advanced cancer admitted to an acute palliative care unit

E.H. Jung, Y. Park,Y.J. Kim, S. Yi, K. Kim,J. Oh,S. Lee, B. Kang, K.J. Suh,J.Y. Lee,J-W. Kim,S.H. Kim,

Annals of Oncology (2023): S891-S891

引用0浏览0引用

P2.09-03 Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis

T. Reungwetwattana,B.C. Cho,K.H. Lee,Y.K. Pang, C.H. Fong,J.H. Kang,Y.-G. Lee,C.S. Lim,P. Danchaivijitr, Y.N. Lim,Y. Lee,S.H. How,

Journal of Thoracic Oncology（2023）

引用0浏览0引用

LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

B.C. Cho, E. Felip, A.I. Spira, N. Girard,J-S. Lee,S-H. Lee, Y.V. Ostapenko, P. Danchaivijitr, B. Liu, A. Alip, E.P. Korbenfeld, J. Dias,

Annals of Oncology (2023): S1306-S1306

引用1浏览0引用

1333P A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations

M.H. Hong, A.I. Spira, K.H. Lee, E.K. Cho,J-Y. Han, B.Y. Shim,J-S. Lee, S.C-H. Kao,S-W. Kim, A. Khattak, M. Patel, R. Xu,

Annals of Oncology (2023): S769-S769

引用0浏览0引用

41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)

H. Borghaei, D. Balli, L. Paz-Ares, M. Reck,S.S. Ramalingam, J.R. Brahmer,T-E. Ciuleanu, A. Pluzanski,J-S. Lee, J. Gainor, M. Schenker, A. Schoenfeld,

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S64-S65

引用0浏览0引用

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

H. Borghaei,T.-E. Ciuleanu,J.-S. Lee,A. Pluzanski,R. Bernabe Caro,M. Gutierrez, Y. Ohe,M. Nishio, J. Goldman, N. Ready, D.R. Spigel,S.S. Ramalingam,

Ann Oncol（2023）

引用5浏览0WOS引用

5-year Survival Data in the First-line (1L) Treatment of advanced non-small cell Lung Cancer (mNSCLC) with Nivolumab (NIVO) plus Ipilimumab (IPI) vs Chemotherapy (chemo): Results of the CheckMate 227 Study

B. Jaeschke, J. R. Brahmer,J. S. Lee, T. E. Ciuleanu,R. B. Caro, M. Nishio, L. Urban, C. Audigier-Valette, L. Lupinacci, R. Sangha, L. G. Paz-Ares, M. Reck,

ONCOLOGY RESEARCH AND TREATMENTno. SUPPL 2 (2022)

引用0浏览0引用

459MO Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation

M. Patel,J-S. Lee,M.J. De Miguel, T. Burns,A. Falcon Gonzalez,T.W. Kim, M.G. Krebs,H. Prenen,E. Shacham Shmueli,J. Desai,P. Lorusso,A. Sacher,

ANNALS OF ONCOLOGY（2022）

引用2浏览0引用

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients

K J O'Byrne,K H Lee,S-W Kim,K Park, M Nishio,H Sakai, Y Ohe,T Fukuhara,J-H Kang, H Daga,C-J Yu, K Hotta,

ESMO Open（2022）

引用6浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn